Results overview: Found 9 records in 0.01 seconds.
Articles, 9 records found
Articles 9 records found  
1.
10 p, 384.2 KB Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy / Ilson, David H. (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Prokharau, Aliaksandr (Minsk City Clinical Oncology Dispensary) ; Arkenau, Hendrik-Tobias (University College London) ; Ghidini, Michele (Azienda Ospedaliera di Cremona) ; Fujitani, Kazumasa (Osaka General Medical Center) ; Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Thuss-Patience, Peter (Charité - Universitätsmedizin Berlin) ; Beretta, Giordano D. (Humanitas Gavazzeni) ; Mansoor, Wasat (The Christie NHS Foundation Trust (Regne Unit)) ; Zhavrid, Edvard (Alexandrov National Cancer Centre of Belarus) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; George, Ben (Medical College of Wisconsin) ; Catenacci, Daniel (University of Chicago) ; McGuigan, Sandra (Taiho Oncology Inc) ; Makris, Lukas (Stathmi Inc) ; Doi, Toshihiko (National Cancer Center Hospital East (Japó)) ; Shitara, Kohei (National Cancer Center Hospital East (Japó)) ; Universitat Autònoma de Barcelona
This subgroup analysis of a randomized clinical trial compares trifluridine/tipiracil treatment with placebo for progression-free and overall survival among patients with previously treated metastatic gastric or gastroesophageal junction cancer who had or had not undergone gastrectomy. [...]
2019 - 10.1001/jamaoncol.2019.3531
JAMA Oncology, Vol. 6 (october 2019)  
2.
5 p, 637.4 KB Educational needs in gastrointestinal cancer : a consensus position paper from the ESMO Gastrointestinal Cancer Faculty / Lordick, Florian (Leipzig University Medical Center) ; Obermannova, Radka (Masaryk University) ; Vola, Doris (European Society for Medical Oncology) ; Douillard, Jean-Yves (European Society for Medical Oncology) ; Mcgregor, Keith (European Society for Medical Oncology) ; Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Ciardiello, Fortunato (Second University of Naples) ; Cervantes, Andrés (Universitat de València)
Gastrointestinal (GI) cancers are common in all parts of the world. Effective prevention and early detection of GI cancers are not universally implemented. Therefore, it must be anticipated that the incidence and the mortality of GI cancers will remain high within the next decades. [...]
2019 - 10.1136/esmoopen-2019-000533
ESMO open, Vol. 4 (july 2019)  
3.
11 p, 726.2 KB Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 / Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Amonkar, Mayur (Merck & Co., Inc.. Center for Observational and Real World Evidence) ; Fuchs, Charles S. (Yale School of Medicine. Yale Cancer Center) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Özgüroğlu, Mustafa (Istanbul University-Cerrahpaşa. Department of Internal Medicine, Medical Oncology, and Clinical Trial Unit) ; Bang, Yung-Jue (Seoul National University College of Medicine. Department of Internal Medicine) ; Chung, Hyun Cheol (Yonsei University College of Medicine. Department of Medical Oncology) ; Muro, Kei (Aichi Cancer Center Hospital) ; Goekkurt, Eray (University Cancer Center Hamburg. North-German Trial Center for Innovative Oncology) ; Benson, Al B. (Northwestern University. Robert H. Lurie Comprehensive Cancer Center) ; Sun, Weijing (University of Kansas. Department of Internal Medicine and Medical Oncology) ; Wainberg, Zev A. (David Geffen School of Medicine at UCLA. Department of Medicine and Hematology and Oncology) ; Norquist, Josephine M. (Merck & Co., Inc.. Center for Observational and Real World Evidence) ; Chen, Xinqun (Merck & Co., Inc.. Department of Medical Oncology) ; Shih, Chie-Schin (Merck & Co., Inc.. Department of Medical Oncology) ; Shitara, Kohei (National Cancer Center Hospital. Department of Gastrointestinal Oncology) ; Universitat Autònoma de Barcelona
In the primary analysis population (i. e. , PD-L1 combined positive score [CPS] ≥ 1) of the phase 3 KEYNOTE-061 study (NCT02370498), pembrolizumab did not significantly prolong overall survival or progression-free survival. [...]
2021 - 10.1007/s10120-021-01200-w
Gastric Cancer, Vol. 24 (august 2021) , p. 1330-1340  
4.
8 p, 1.6 MB Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer : a subgroup analysis from the phase 3 TAGS study / Mansoor, Wasat (The Christie NHS Foundation Trust) ; Arkenau, Hendrik-Tobias (University College London) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Shitara, Kohei (National Cancer Center Hospital East) ; Thuss-Patience, Peter (Charité - Universitätsmedizin Berlin) ; Cuffe, Sinead (St. James's Hospital ( Dublín, Irlanda)) ; Dvorkin, Mikhail (Omsk Regional Clinical Centre of Oncology) ; Park, David (St, Joseph Heritage Healthcare) ; Ando, Takayuki (University of Toyama) ; Van Den Eynde, Marc (UCL Cliniques Universitaires Saint-Luc) ; Beretta, Giordano D. (Humanitas Gavazzeni) ; Zaniboni, Alberto (Fondazione Poliambulanza-Istituto Ospedaliero) ; Doi, Toshihiko (National Cancer Center Hospital East) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Ilson, David H. (Memorial Sloan Kettering Cancer Center) ; Makris, Lukas (Stathmi, Inc, New Hope, PA USA) ; Benhadji, Karim A. (Taiho Oncology) ; Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Universitat Autònoma de Barcelona
Patients with advanced gastroesophageal junction cancer (GEJC) have poor survival outcomes, and GEJC-specific data from trials evaluating agents in gastric cancers (GCs) as a whole are lacking. Trifluridine/tipiracil (FTD/TPI) was approved for previously treated metastatic GC or GEJC (mGC/mGEJC) based on results of the phase 3 TAGS trial. [...]
2021 - 10.1007/s10120-021-01156-x
Gastric Cancer, Vol. 24 (march 2021) , p. 970-977  
5.
9 p, 1.3 MB Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies : exploratory analyses of the RAISE trial and validation in an electronic medical record data set / Grothey, Axel (Mayo Clinic) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Bodoky, Gyorgy (St László Hospital (Hongria)) ; Ciuleanu, Tudor Eliade (The Oncology Institute Prof Dr Ion Chiricută and Iuliu Hațieganu University of Medicine and Pharmacy) ; García-Carbonero, Rocío (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Muro, Kei (Aichi Cancer Center Hospital) ; Mytelka, Daniel S. (Formerly of Eli Lilly and Company) ; Li, Li (Eli Lilly and Company) ; Lipkovich, Olga (Eli Lilly and Company) ; Hsu, Yanzhi (Eli Lilly and Company) ; Sashegyi, Andreas (Eli Lilly and Company) ; Ferry, David (Eli Lilly and Company) ; Nasroulah, Federico (Eli Lilly Argentina) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. [...]
2018 - 10.1136/esmoopen-2018-000347
ESMO open, Vol. 3 (april 2018)  
6.
19 p, 418.6 KB Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer : Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study / Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Huijberts, Sanne (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Grothey, Axel (West Cancer Center, Germantown, TN) ; Yaeger, Rona (Memorial Sloan Kettering Cancer Center) ; Cuyle, Pieter-Jan (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Elez, Elena (Vall d'Hebron Institut d'Oncologia) ; Fakih, Marwan (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ; Montagut, Clara (Institut Hospital del Mar d'Investigacions Mèdiques) ; Peeters, Marc (University Hospital Antwerp (Bèlgica)) ; Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ; Wasan, Harpreet (Hammersmith Hospital (Londres)) ; Desai, Jayesh (Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia) ; Ciardiello, Fortunato (University of Campania "Luigi Vanvitelli" (Nàpols, Itàlia)) ; Gollerkeri, Ashwin (Array BioPharma Inc) ; Christy-Bittel, Janna (Array BioPharma Inc) ; Maharry, Kati (Array BioPharma Inc) ; Sandor, Victor (Array BioPharma Inc) ; Schellens, Jan H. M. (Utrecht University) ; Kopetz, Scott (The University of Texas MD Anderson Cancer Center, Houston, TX) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Vall d'Hebron Institut de Recerca (VHIR)
To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial ( identifier: ; European Union Clinical Trials Register identifier: EudraCT2015-005805-35). [...]
2019 - 10.1200/JCO.18.02459
Journal of Clinical Oncology, Vol. 37 (march 2019) , p. 1460-1469  
7.
16 p, 1.5 MB Health-related Quality of Life in the Phase III LUME-Colon 1 Study : Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses / Lenz, Heinz Joseph (Division of Medical Oncology. USC Norris Comprehensive Cancer Center) ; Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ; Yoshino, Takayuki (Department of Gastroenterology and Gastrointestinal Oncology. National Cancer Center Hospital East) ; Lonardi, Sara (Phase 1 Trial Unit and Medical Oncology Unit 1. Istituto Oncologico Veneto IRCCS) ; Falcone, Alfredo (Department of Oncology. University of Pisa) ; Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Sobrero, Alberto (Ospedale Policlinico San Martino IRCCS) ; Hastedt, Claudia (Boehringer Ingelheim International GmbH) ; Peil, Barbara (Boehringer Ingelheim Pharma GmbH & Co. KG) ; Voss, Florian (Boehringer Ingelheim Pharma GmbH & Co. KG) ; Griebsch, Ingolf (Boehringer Ingelheim International GmbH) ; Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Universitat Autònoma de Barcelona
Based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) outputs from the LUME-Colon 1 study, we compared and discussed different statistical methods for evaluating health-related quality of life data in oncology clinical trials. [...]
2019 - 10.1016/j.clcc.2019.08.005
Clinical Colorectal Cancer, Vol. 18 Núm. 4 (december 2019) , p. 269-279.e5  
8.
13 p, 2.9 MB Genomic profiling of NETs : A comprehensive analysis of the RADIANT trials / Yao, James (University of Texas MD Anderson Cancer Center) ; Garg, Amit (Novartis Institutes for Biomedical Research) ; Chen, David (Novartis Pharmaceuticals Corporation) ; Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ; Engstrom, Paul (Fox Chase Cancer Center) ; Pommier, Rodney (Oregon Health and Science University) ; Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Singh, Simron (Odette Cancer Center. Sunnybrook Health Sciences Center) ; Fazio, Nicola (European Institute of Oncology) ; He, Wei (Novartis Pharmaceuticals Corporation) ; Riester, Markus (Novartis Institutes for Biomedical Research) ; Patel, Parul (Novartis Pharmaceuticals Corporation) ; Voi, Maurizio (Novartis Pharmaceuticals Corporation) ; Morrissey, Michael (Novartis Institutes for Biomedical Research) ; Pavel, Marianne (University of Erlangen-Nuremberg) ; Helmut Kulke, Matthew. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Universitat Autònoma de Barcelona
Neuroendocrine tumors (NETs) have historically been subcategorized according to histologic features and the site of anatomic origin. Here, we characterize the genomic alterations in patients enrolled in three phase 3 clinical trials of NET of different anatomic origins and assess the potential correlation with clinical outcomes. [...]
2018 - 10.1530/ERC-18-0332
Endocrine-Related Cancer, Vol. 26 Núm. 4 (2018), p. 391-403  
9.
7 p, 770.6 KB Proxies of quality of life in metastatic colorectal cancer : analyses in the RECOURSE trial / Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Falcone, Alfredo (Azienda Ospedaliero-Universitaria Pisana) ; García Carbonero, Rocio (Hospital Universitario 12 de Octubre (Madrid)) ; Komatsu, Yoshito (Hokkaido University Hospital) ; Pastorino, Alessandro (IRCCS AOU San Martino IST) ; Peeters, Marc (University Hospital Antwerp (Bèlgica)) ; Shimada, Yasuhiro (National Cancer Center Hospital) ; Yamazaki, Kentaro (Shizuoka Cancer Center) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Zaniboni, Alberto (Fondazione Poliambulanza) ; Amellal, Nadia (Institut de Recherches Servier) ; Kanehisa, Akira (Institut de Recherches Servier) ; Winkler, Robert (Taiho Oncology) ; Makris, Lukas (Taiho Oncology) ; Mayer, Robert J. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Ohtsu, Atsushi (National Cancer Center Hospital East) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina)
In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). [...]
2017 - 10.1136/esmoopen-2017-000261
ESMO open, Vol. 2 (november 2017)  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.